Overview

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

Status:
Not yet recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma. Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness and safety

Phase:

Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel